Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial

NCT01653067 is registered in ClinicalTrials.gov with Mathias Witzens-Harig as lead sponsor.

NCT NCT01653067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01653067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial
Lead sponsor
Mathias Witzens-Harig
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2012
Completion date
July 31, 2018
Enrollment
88 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma